
TORL BioTherapeutics Reports Positive Phase 1 Data for Ovarian Cancer Drug
A combination of the experimental ADC ixotatug vedotin and bevacizumab achieved a 32.1% objective response rate in patients with recurrent ovarian cancer, according to early-stage clinical data presented at the ESMO Gynaecological Cancers Congress 2026 in Los Angeles this week.
























